CM082

DRUG5 trials

Conditions

Advanced Malignant Solid TumorsAge-Related Macular DegenerationMyopic Choroidal NeovascularisationRenal Cell Cancer MetastaticRenal Cell Carcinoma Recurrent

Phase 1

Study of the Combination of CM082 With Everolimus in Patients With mRCC

NCT02577458

AnewPharmaRenal Cell Carcinoma Recurrent

Start: 2015-09-30End: 2018-06-30Target: 18Updated: 2018-01-10

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

NCT03792958

AnewPharmaAdvanced Malignant Solid Tumors

Start: 2019-02-26End: 2023-06-30Updated: 2022-11-14

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

SuspendedNCT04222842

AnewPharmaMyopic Choroidal Neovascularisation

Start: 2019-12-18End: 2021-12-30Target: 96Updated: 2021-03-10

Phase 2

Safety and Tolerability of Oral CM082 in Patients With wAMD

NCT03710863

AnewPharmaAge-Related Macular Degeneration

Start: 2018-11-22End: 2022-01-01Target: 64Updated: 2020-01-13

Phase 3

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

NCT03095040

AnewPharmaRenal Cell Cancer Metastatic

Start: 2016-12-16End: 2021-12-31Target: 390Updated: 2021-02-08

Related Papers

Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).

2022-11-0113 citations

Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial.

Journal of Clinical Oncology2021-05-201 citations

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.

2020-04-239 citations

Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.

Journal of Clinical Oncology2018-05-20

A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma.

Journal of Clinical Oncology2017-05-207 citations